Onkos Surgical
Onkos Surgical develops implants, instruments, and personalized surgical planning solutions for musculoskeletal oncology and complex orthopedic reconstruction, serving orthopedic oncologists and complex revision surgeons at over 350 US academic medical institutions.
- Company typePrivate
- Founded2015
- HeadquartersParsippany, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Onkos Surgical does
Onkos Surgical is a privately held medical device company founded in 2015 and headquartered in Parsippany, New Jersey, that develops implants, instruments, and digital planning tools for musculoskeletal oncology and complex orthopedic reconstruction. Its portfolio centers on the ELEOS Limb Salvage System, which is augmented by the BioGrip 3D-printed porous collar technology, the My3D personalized solutions platform, and the JTS Extendible Prosthesis for pediatric bone cancer patients acquired from Stryker in 2022. The company's most differentiated asset is NanoCept, a 70-nanometer antibacterial implant coating that received the first FDA De Novo authorization for an antibacterial coating on orthopedic implants in April 2024, demonstrating up to 99.999% bacterial kill rates against common operating-room pathogens.
The business generates revenue primarily through direct sales of implants and personalized surgical planning services to over 350 US academic medical institutions, supported by a field sales and clinical support team. Pricing is quote-based, determined through hospital procurement, with multi-year contract cadence and no publicly disclosed list pricing. Go-to-market is enterprise field sales augmented by a surgeon-driven adoption model that uses KOL relationships, medical conference presence (AAOS, MSTS), and high-touch case planning through the uDesign ecosystem. Distribution includes a channel partnership with Integrum AB for the OPRA osseointegration device, and a 2018 strategic agreement with 3D Systems powers the My3D virtual surgical planning platform.
Capital structure reflects a venture-backed, commercially scaling company: cumulative equity raised since 2015 exceeds $80M across multiple rounds led by 1315 Capital and Canaan Partners, supplemented by a $35M venture loan facility from Horizon Technology Finance in January 2025 to fund NanoCept commercialization. The company holds multiple FDA clearances (De Novo plus several 510(k)s), maintains a 51-100 employee headcount, and is actively investing in manufacturing capacity through a new Parsippany innovation center and a dedicated NanoCept Innovation Center in Bridgewater Township opened December 2025.
Onkos Surgical firmographics
Firmographics- Name
- Onkos Surgical
- Legal name
- Onkos Surgical, Inc.
- Website
- https://onkossurgical.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Onkos Surgical develops implants, instruments, and personalized surgical planning solutions for musculoskeletal oncology and complex orthopedic reconstruction, serving orthopedic oncologists and complex revision surgeons at over 350 US academic medical institutions.
- Ownership category
- akta.pro rank
Onkos Surgical industry classification
Industry- Product category
- Orthopedic Oncology Implants
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)
- akta.pro secondary industries
- Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA), Medical & Dental 3D Printing Services (patient-specific devices, dental labs) (IMAAADAG)
Keywords
Where Onkos Surgical is headquartered
LocationHeadquarters
- HQ city
- Parsippany
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Onkos Surgical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Medical Device Sales - Implants: Onkos Surgical generates revenue primarily through the sale of orthopedic implants and surgical devices for limb salvage, tumor reconstruction, and complex revision procedures. Products include the ELEOS Limb Salvage System, BioGrip implants, NanoCept-coated implants, My3D personalized pelvic reconstruction implants, and JTS extendible prostheses. Revenue is generated through direct hospital purchasing relationships with academic medical institutions.
- Personalized Solutions Services: Revenue from patient-specific 3D planning services, personalized implant design, and surgical planning collaboration. The My3D platform provides revenue through dedicated Patient Solutions Engineers facilitating surgical planning, implant design services, and coordination. Includes preoperative planning, 3D modeling, implant customization, and workflow optimization services.
- JTS Pediatric Prosthesis: Revenue from extendible prostheses designed for pediatric bone cancer patients. The JTS system provides a growing implant with significant clinical evidence that achieves lower limb length equality over time through non-invasive magnetic lengthening, eliminating need for multiple lengthening surgeries.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom implant pricing based on patient-specific requirements and procedure complexity |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Onkos Surgical product offering
Product offeringCore offering
Onkos Surgical designs, manufactures, and sells specialized orthopedic implants and surgical instruments for musculoskeletal oncology and complex revision procedures, including the ELEOS Limb Salvage System, BioGrip 3D-printed implants, NanoCept antibacterial-coated implants, and JTS pediatric extendible prostheses. The company also provides personalized surgical planning services through its My3D platform, including virtual surgical planning, patient-specific 3D-printed implants, and case support for orthopedic oncologists. Products are sold directly to academic medical institutions and hospitals for limb salvage procedures in bone cancer and complex reconstruction patients.
Product overview
Onkos Surgical offers a unified platform-plus-modules architecture for Precision Orthopaedics focused on musculoskeletal oncology and complex orthopaedic reconstruction. The core ELEOS Limb Salvage System serves as the primary implant portfolio, which integrates with BioGrip 3D Printed Technology for enhanced osseointegration and soft tissue attachment. The NanoCept Antibacterial Implant Technology represents a differentiated platform technology that can be applied across implant components to address intraoperative bacterial contamination. The My3D Personalized Solutions platform provides digital surgical planning and patient-specific 3D printed implants and instrumentation. The JTS Extendible Prosthesis addresses pediatric limb reconstruction needs. Supporting these are uDesign surgical planning tools and MyTray workflow solutions. Over 350 leading academic medical institutions in the US utilize Onkos solutions for complex revision and tumor orthopaedic cases.
Differentiator
Problem solved
Functional benefit
Brands
- ELEOS Limb Salvage System: A modular total joint system for patients with bone loss due to tumor, trauma, or revision surgery.
- BioGrip
- NanoCept
- My3D
- JTS Extendible Prosthesis
- uDesign
- GenVie
Products and services
- ELEOS Limb Salvage System Comprehensive end-to-end limb salvage solution featuring modular components for distal femur, proximal femur, proximal tibia, and total femoral replacement. Designed to address key clinical challenges including soft tissue failures and aseptic loosening through streamlined solutions that reduce operative complexity.
- NanoCept Antibacterial Implant Technology First FDA-granted antibacterial coating technology for orthopaedic implants. Proprietary 70-nanometer-thick coating based on quaternary ammonium molecules that kills bacteria upon contact without eluting, demonstrating up to 99.999% kill rate against bacteria commonly found in operating room environment.
- My3D Personalized Solutions Digital, patient-matched platform supporting fully personalized repair for complex long-bone and pelvis reconstruction. Includes virtual surgical planning, 3D visualization, 3D printed patient-specific implants and instrumentation, graft-matching services, and comprehensive operative support.
- JTS Extendible Prosthesis Patient-specific, extendible prosthesis for pediatric patients with bone cancer that achieves lower limb length equality over time through non-invasive magnetic lengthening in an outpatient setting. Leading FDA 510(k) cleared device for noninvasive lengthening of pediatric limbs with over 1,700 devices implanted worldwide since 2002.
- ELEOS with BioGrip 3D Printed Technology Limb salvage implant featuring novel 3D-printed BioGrip porous structure designed to support bone and soft tissue ingrowth. Includes modular BioGrip collars with nano HA treatment and anatomically aligned suture holes for directional soft tissue attachment.
- My3D Personalized Pelvic Reconstruction First-of-its-kind 3D-printed and patient-specific system for advanced pelvic reconstruction. Includes 3D printed implants, instruments, and models with advanced planning service for treatment of deformity, trauma, disease, and revisions.
Quantifiable outcome
- 99.999% bacterial kill rate (5-log reduction) in standardized in-vitro testing against bacteria commonly found in operating rooms
- +5 more outcomes
Companies that use Onkos Surgical
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles2 records
Onkos Surgical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Onkos Surgical partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered acquisition, minor, exploratory and core.
- Stryker OrthopedicsacquisitionOnkos Surgical entered into a definitive agreement to acquire the Juvenile Tumour System (JTS) Extendible Prosthesis from Stryker Orthopedics. This acquisition expanded Onkos' pediatric musculoskeletal oncology capabilities and added the JTS growing implant to its portfolio for children with bone cancer.
- Integrum ABminorOnkos Surgical entered a US partnership with Integrum AB to distribute the OPRA osseointegration device. This partnership expanded the company's portfolio to include improved quality of life solutions for amputee patients, complementing the limb salvage focus.
- Insight Medical SystemsexploratoryOnkos Surgical and Insight Medical Systems partnered to explore applications of ARVIS (Augmented Reality Visualization and Information System) in musculoskeletal oncology. Companies conducted a pilot project to assess augmented reality technology for surgical planning and procedure support.
- 3D SystemscoreOnkos Surgical signed a 4-year agreement with 3D Systems (NYSE: DDD) to advance personalized surgical solutions. The agreement provides Onkos priority access to 3D Systems' VSP (Virtual Surgical Planning) Orthopaedics platform. This partnership powers the My3D Personalized Solutions platform launched in 2019 for joint-sparing tumor surgery.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
Onkos Surgical competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Onkos Surgical social profiles
Digital presenceOnkos Surgical compliance and trust
Trust signalCompliance2 records
Onkos Surgical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Onkos Surgical leadership team
Management profileNumber of profiles
Profiles6 records
Onkos Surgical funding detail
Funding detailFunding overview
Funding rounds6 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Onkos Surgical M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Onkos Surgical
What does Onkos Surgical do?
Onkos Surgical designs, manufactures, and sells specialized orthopedic implants and surgical instruments for musculoskeletal oncology and complex revision procedures, including the ELEOS Limb Salvage System, BioGrip 3D-printed implants, NanoCept antibacterial-coated implants, and JTS pediatric extendible prostheses. The company also provides personalized surgical planning services through its My3D platform, including virtual surgical planning, patient-specific 3D-printed implants, and case support for orthopedic oncologists. Products are sold directly to academic medical institutions and hospitals for limb salvage procedures in bone cancer and complex reconstruction patients.
Is Onkos Surgical a public or private company?
Onkos Surgical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Onkos Surgical founded?
Onkos Surgical was founded in 2015. It employs 101 to 250 people.
Where is Onkos Surgical based?
Onkos Surgical is headquartered in Parsippany, United States, in the North America region.
How does Onkos Surgical make money?
Three revenue lines are on record. Medical Device Sales - Implants are the primary driver. The others are personalized Solutions Services and JTS Pediatric Prosthesis.
Does Onkos Surgical have an API?
No public API is recorded for Onkos Surgical.
What industry is Onkos Surgical in?
Onkos Surgical's product category is Orthopedic Oncology Implants. Its primary akta.pro industry code is HLAHAEAJ, 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial), with a secondary code of HLAHAEAA, Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle). Its NAICS code is 339113 and its SIC code is 3842.